Treating Prostate Cancer

Dendreon Corp (DNDN) is a biopharma co. developing immunotherapeutic meds for cancer patients. More on their Provenge drug and how it works which is interesting here

From the chart perspective, DNDN is forming a 6 months Head & Shoulders bottom with 3.60 as the neckline. Will selling Provenge in Europe act as the reversal ? Implied target is $5

Do note the gap above which usually serves as resistance.


STOP searching for trades & subscribe or follow me @theartofchart